Ten-Year Vision and Strategy 30 Years of research on Diseases of Poor Rationale for the New Strategy Context and Content Outlook TDR Presentation 1 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Increased Funding for Infectious Diseases R&D Increased Funding for Infectious Diseases R&D Shiffman 2006. Cohen, et al. 2006. Science 311: 162 -167 TDR Presentation 2 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Disparity with Disease Burden Disparity with Disease Burden Shiffman 2006. TDR Presentation 3 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
TDR Presentation 4 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
A Lot of Players A Lot of Players Cohen, et al. 2006. Science 311: 162 -167 TDR Presentation 5 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Unmet Needs in Global Health Unmet Needs in Global Health Cohen, et al. 2006. Science 311: 162 -167 TDR Presentation 6 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Some significant needs / gaps Some significant needs / gaps Some significant needs / gaps Some significant needs / gaps Empowerment, pivotal role … EDCTP MMV GAELF Trachoma Grand Challenges Microbicides RBM New and New and New and New and New and DNDi New improved improved improved improved improved StopTB knowledge / GATB tools tools tools interventions NIH, Trust, strategies discoveries Research IAVI Global Fund councils, etc… IOWH APOC FIND TDR Presentation 7 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Many Organizations Should be Involved in Global Health Research Which of the following government agencies and other types of organizations should be involved in research designed to improve health around the world? World Health Organization 82% Centers for Disease Control and Prevention 81% Red Cross 68% Doctors Without Borders 66% Pharmaceutical/biotech companies 63% United Nations 59% National Institutes of Health 58% Private foundations 51% Religious organizations 45% USAID 43% State Department 20% Department of Defense 15% Other 3% Attitudes: Global Health Research Charlton Research for Research!America, 2006
Need for new TDR vision/strategy triggered by Need for new TDR vision/strategy triggered by critical trends in global research environment critical trends in global research environment Epidemiological Changes Infectious disease burden Growing regional remains high variation Enhanced Global research Momentum research environment for through new capabilities in infectious players / initiatives DEC's diseases Rise in DEC's left pharmaceutical behind in product priority setting development Complexity and fragmentation TDR Presentation 9 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
TDR Vision TDR Vision http://who.int/tdr To foster: an effective global research effort on infectious diseases of poverty in which disease endemic countries play a pivotal role TDR Presentation 10 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Three Major Strategic Functions to achieve the Three Major Strategic Functions to achieve the objectives objectives • Stewardship for research on infectious diseases of poor populations • Empowerment of researchers and public health professionals from disease endemic countries • Research on Neglected Priority Needs to: Foster innovation for Foster research to Foster research products, develop and evaluate for access to emphasizing DEC interventions in interventions engagement real-life settings TDR Presentation 11 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Conceptual framework for the strategy TDR Presentation 12 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Empowerment Empowerment • Empowerment of researchers and policy makers from disease endemic countries, going beyond classical research capacity building towards strengthening the role of disease endemic countries in health research planning, priority setting, research implementation and translation of research findings into policy and practice TDR Presentation 13 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Empowerment for DEC: Utilizing Capacity Empowerment for DEC: Utilizing Capacity for Ethical Review for Ethical Review Public sector Public sector • Guidelines TDR, OHRP Private Sector Private Sector NGO - EFGCP NGO - EFGCP • Training - IFPMA - IFPMA - INCLEN - INCLEN - Pharm - Pharm - IOWH - IOWH - WIRB WIRB • Network FERCAP FERCAP FOCUS SIDCER SIDCER National National • Regional forums Chapters Chapters FLACIES PABIN FLACIES PABIN • National forums National National FECCIS Chapters Chapters National • Local ownership! Chapters • Legislative changes enacted or under preparation – Korea, Thailand, Indonesia, CIS (Armenia, Azerbaijan, Byelorussia, Georgia, Kazakhstan, Kyrgyz Republic, Moldova, Russia, Tajikistan, Ukraine, Uzbekistan), India – Laos and Cambodia have established National Ethics Committees (no Ethical Committees before) • Attempts to assist other regions under way with partners TDR Presentation 14 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Network for clinical trial support Network for clinical trial support Monitoring Ethical review Data management TDR Presentation 15 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
BL 3 – Lead discovery BL 3 – Lead discovery for infectious diseases of poverty for infectious diseases of poverty Overall objective: to facilitate and support the discovery of new drug leads for infectious diseases of poverty through networks and partnerships between pharmaceutical companies, academia and DEC institutes Specific Objectives End Products - Identify quality lead compounds and - 10 drug leads by 2013 facilitate their transfer - Open access database of targets - Identify candidates for antihelmintics - Prioritized Dx targets by 2009 - Prioritized list of Dx targets - Helminth initiative functional - Global coordination through network and partnership model - 2 antihelminthic candidates by 2013 - Promote technology transfer and - Coordinated drug discovery through drug discovery in DECs networks/partnerships TDR Presentation 16 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
BL 4 – Innovation for Product Development in DECs BL 4 – Innovation for Product Development in DECs Overall objective: To facilitate the transfer of health innovation technologies and foster the discovery and development of novel drugs, diagnostic tests and other products in DECs Specific Objectives End Products (2013) - 9 partnership R&D projects with - Develop projects for discovery DEC leadership and development by DEC teams - 3 to 5 DEC centres with of investigators and institutions international renowned capacity for - Develop platform to support DEC screening/ lead identification leadership and partnerships for - Technology for target validation, discovery and development lead optimization and toxicology establlished in 5 DEC centres - Facilitate south-based spin-offs - Spin-offs of at least 4 project -Products developed or in late stage partnerships in DECs of development - 2 Dx tests and 2 drug candidates through DEC led partnerships TDR Presentation 17 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Research on Neglected Priorities Research on Neglected Priorities TDR Presentation 18 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
Support for elimination of Visceral Support for elimination of Visceral Leishmaniasis Leishmaniasis New tools (miltefosine / diagnostics) stimulate India / Nepal / Bangladesh to sign MoU for elimination of VL by 2015 • Research acknowledged as integral • Local ownership of research critical • Close work with HQ and SEARO • A major 'research activity' for 2006-7 to assist elimination strategy • Drugs alone and in combination • Integration with diagnostics • Implementation Research TDR Presentation 19 30th SEA-ACHR, Jakarta, Indonesia 14-16 March, 2007
BL 10 – Research to support elimination BL 10 – Research to support elimination of Kala azar from the Indian subcontinent of Kala azar from the Indian subcontinent Overall objective: To develop intervention tools and generate evidence for influencing policies for elimination of visceral leishmaniasis Specific Objectives End Products - Play a stewardship role to define - Functional link with RTAG/countries to needs, priorities and provide advise on tools/strategies for elimination technical guidance to research for - Consensus on VL elimination strategies elimination of visceral leishmaniasis - Optimal and most cost-effective - Generate evidence on the most elimination strategy defined cost-effective elimination strategies - Cost-effective and sustainable vector using optimal interventions across control strategy treatment and vector control - Cost-effective strategy for case - Develop and evaluate new and management improved diagnostics, drugs and - Improved interventions: safe and combination therapies affordable combination therapy TDR Presentation 20 30th SEA-ACHR, Jakarta, Indonesia STAC 2007 14-16 March, 2007 Group 3 on Research Business Lines
Recommend
More recommend
